Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406

Fostamatinib is the first approved spleen tyrosine kinase inhibitor for chronic immune thrombocytopenia. This review summarizes the clinical development, pharmacokinetics, pharmacodynamics, drug–drug interactions, adverse events, and comprehensive analyses of fostamatinib. While integrating these fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsukane, Ryosuke, Suetsugu, Kimitaka, Hirota, Takeshi, Ieiri, Ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250994/
https://www.ncbi.nlm.nih.gov/pubmed/35781630
http://dx.doi.org/10.1007/s40262-022-01135-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250994/
https://www.ncbi.nlm.nih.gov/pubmed/35781630
http://dx.doi.org/10.1007/s40262-022-01135-0

Ejemplares similares